Aggressive B-cell lymphoma with IGH/MYC, IGH/BCL2, and IGH/CCND1 translocations

DOI Web Site PubMed

Bibliographic Information

Other Title
  • IGH/MYC, IGH/BCL2およびIGH/CCND1転座を有するaggressive B細胞リンパ腫
  • 症例報告 第9回日本血液学会関東甲信越地方会 優秀演題 IGH/MYC, IGH/BCL2およびIGH/CCND1転座を有するaggressive B細胞リンパ腫
  • ショウレイ ホウコク ダイ9カイ ニホン ケツエキ ガッカイ カントウ コウシンエツチホウカイ ユウシュウ エンダイ IGH/MYC, IGH/BCL2 オヨビ IGH/CCND1テンザ オ ユウスル aggressive Bサイボウ リンパシュ

Search this article

Abstract

<p>A 70-year-old man was admitted to our hospital due to fever, lymphadenopathy, and leukocytosis. White blood cell count was 22,700/µl with 92% blastoid cells. Bone marrow examination revealed abnormal lymphoid cell expansion. Abnormal cells expressed surface CD5 (dim), CD10, CD19, CD20, CD23 (dim) antigens, and kappa immunoglobulin light chains. Cytogenetic analysis of bone marrow cells at the time of diagnosis showed t (11:14) (q13;q32), t (14;18) (q32;q21), and t (8;14;18) (q24;q32;q21). Fluorescence in situ hybridization analyses of bone marrow identified translocations of IGH/MYC, IGH/BCL2, and IGH/CCND1. The patient was diagnosed with aggressive B-cell lymphoma with IGH/MYC, IGH/BCL2, and IGH/CCND1 translocation and was treated with various chemotherapies including R-CHOP, R-ESHAP, DA-EPOCH-R, R-hyper-CVAD, and radiotherapy. However, the lymphoma recurred after every chemotherapy session. Finally, he died after 6 months after first admission. Double-hit lymphoma/triple-hit lymphoma has previously been reported to present with an aggressive clinical course. In the present case, co-existence of IGH/CCND1, IGH/MYC, and IGH/BCL2 is very rare. Further clinical and biological investigations are necessary to establish an optimal treatment strategy.</p>

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 60 (10), 1425-1430, 2019

    The Japanese Society of Hematology

Keywords

Details 詳細情報について

Report a problem

Back to top